# ALZHEIMER'S

## RESEARCH PRODUCTS

TORONTO RESEARCH CHEMICALS

WWW.TRC-CANADA.COM

# ALZHEIMER'S RESEARCH TARGET PRODUCTS

SCAN THIS QR CODE WITH YOUR SMARTPHONE TO VIEW ALL PRODUCTS FOR ALZHEIMER'S RESEARCH ON THE TRC WEBSITE.

trc canada

TORONTO RESEARCH CHEMICALS

# ALZHEIMER'S DISEASE RESEARCH PRODUCTS

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with a relentless progression. AD pathogenesis is believed to be triggered by the accumulation of the amyloid-β peptide (Aβ), which is due to overproduction of Aβ and/or the failure of clearance mechanisms. Several approaches aimed at inhibiting disease progression have advanced to clinical trials for this unmet medical disorder of neurology.

Among these, strategies targeting the production and clearance of the amyloid-β peptide — a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis — are the most advanced. Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated preclinical and clinically. We, at Toronto Research Chemicals offer a wide product range for designing different strategies for AD.

| Cat No. | Compound Name | Biochemical/ Physiological Action |
|---|---|---|
| **Acetylcholine Nicotinic Receptors** | | |
| V098490 | Varenicline Tartrate | *α4β2 partial agonist* |
| E582200 | Epibatidine | *α4β2 and α3β4 agonist* |
| D452485 | Dihydro-β-erythroidine Hydrobromide | *α4 nicotinic receptors Antagonist* |
| P270280 | Pentafluorobenzene | *α4β2 Antagonist* |
| **Amyloid β** | | |
| A604380 | (S)-7-Amino-5H,7H-dibenzo[b,d]azepin-6-one | *γ-secretase inhibitor, Aβ levels* |
| D422600 | Dibenzazepine | *γ-secretase inhibitor, Aβ 42 levels* |
| B596070 | BMS 299897 | *γ-secretase inhibitor, Aβ 40 levels* |
| D193290 | DAPT | *Aβ oligomer Inhibitor* |
| **Autophagy** | | |
| M275904 | 3-Methyl Adenine | *Autophagy inhibitor via PI-3K* |
| Q550550 | 6-Chloro-1,2,3,4-tetrahydro-N-[2-(4-methyl-1-piperazinyl)ethyl]-9-acridinamine | *Autophagy & lysosomal activity inhibitor* |
| M275905 | 3-Methyl Adenine-d3 | *Autophagy inhibitor via PI-3K (L)* |
| **Cholinesterase** | | |
| A178280 | O-Acetylgalanthamine | *Cholinesterase inhibitor* |
| A190260 | Acotiamide Hydrochloride | *BChE inhibitor* |
| C080100 | Caffeine | *Acetylcholinesterase inhibitor* |
| T773855 | Trichlorfon | *Dual AChE and BChE inhibitor* |
| **Cyclooxygenases (COX)** | | |
| B679280 | N-[4-(2-Bromoacetyl)phenyl]methanesulfonamide | COX 1 inhibitor |
| M264695 | Desmethyl Naproxen | Selective COX inhibitor |
| N200500 | Nabumetone | Non Selective COX inhibitor |
| **DYRK** | | |
| H105250 | Harmine | Selective $DYRK_{1A}$ Inhibitor |
| I655600 | INDY | Potent and Selective $DYRK_{1A}$ Inhibitor |
| P755945 | ProINDY | Non Selective $DYRK_{1A}$ Inhibitor |
| A795155 | AZ191 | Potent $DYRK_{1B}$ Inhibitor |
| **Glutamate Receptors** | | |

TORONTO RESEARCH CHEMICALS

# ALZHEIMER'S DISEASE RESEARCH PRODUCTS

| | | |
|---|---|---|
| A603550 | 1-Aminocyclopropane-1-carboxylic Acid | *NMDA Agonist* |
| D525365 | DL-AP5 Sodium Salt | *NMDA Antagonist* |
| R143450 | Remacemide Hydrochloride | *NMDA Antagonist* |
| P285520 | Perampanel | *AMPA Antagonist* |
| I232500 | IDRA-21 | *AMPA Modulator* |
| A634275 | Ampalex | *AMPA Modulator* |
| B129500 | BDP 37 | *AMPA Modulator* |
| M311570 | (2S,3R)-3-Methylglutamic Acid Hydrochloride Salt | *Kainate Agonist* |
| B684195 | Bromoethane | *Kainate Antagonist* |
| B684198 | Bromoethane-d3 | *Kainate Antagonist* |
| **Metabotropic Glutamate Receptors** | | |
| L486690 | LY 367385 | $mGlu_1$ *Antagonist (Group I)* |
| R637400 | Ro 67-4853 | $mGlu_1$ *Antagonist (Group I)* |
| V787575 | VU 0483605 | $mGlu_1$ *Antagonist (Group I)* |
| M745805 | MPEP Hydrochloride | $mGlu_5$ *Antagonist (Group I)* |
| R637400 | Ro 67-4853 | $mGlu_5$ *Antagonist (Group I)* |
| A171990 | Acetyl L-Carnitine Hydrochloride | $mGlu_2$ *Antagonist (Group II)* |
| A171991 | Acetyl L-Carnitine-13C3 Chloride | $mGlu_2$ *Antagonist (Group II)* |
| A171992 | Acetyl L-Carnitine-d3 Hydrochloride | $mGlu_2$ *Antagonist (Group II)* |
| L486680 | LY 354740 Hydrate | $mGlu_{2/3}$ *Antagonist (Group II)* |
| L486720 | LY 379268 | $mGlu_3$ *Antagonist (Group II)* |
| M425325 | ML-289 | $mGlu_3$ *Antagonist (Group II)* |
| C379860 | N-(3-Chlorophenyl)-2-pyridinecarboxamide | $mGlu_4$ *Antagonist (Group III)* |
| T012600 | TCN 238 | $mGlu_4$ *Antagonist (Group III)* |
| V787555 | VU 0364439 | $mGlu_4$ *Antagonist (Group III)* |
| V787575 | VU 0483605 | $mGlu_4$ *Antagonist (Group III)* |
| X743850 | XAP 044 | $mGlu_7$ *Antagonist (Group III)* |
| L473475 | LSN 2463359 | $mGlu_8$ *Antagonist (Group III)* |
| **GSK3 (Glycogen Synthase Kinase 3)** | | |
| A626820 | 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol | Potent GSK-3β inhibitor |
| A808085 | AZD1080 | Selective GSK-3 inhibitor |
| A808095 | A808095 | GSK-3α/β inhibitor |
| C367705 | 2-Chloro-4(1H)-pyrimidinone | Inhibits GSK-3 in vivo |
| **γ-Secretase** | | |
| B682305 | 3-Bromo-2-chloropyridine | γ-Secretase Modulator |
| D422600 | Dibenzazepine | Potent γ-Secretase Inhibitor |
| B596070 | BMS 299897 | Non selective Aβ40 and Aβ42 inhibitor |
| D193290 | DAPT | γ-Secretase Inhibitor |

**Toronto Research Chemicals**
2 Brisbane Rd, Toronto, ON
Canada M3I 2I8

Toronto Research Chemicals
products for innovative research